ReShape Lifesciences (RSLS) Registration Filing summary

Company overview and business model

• Operates as a clinical-stage specialty pharmaceutical company focused on immune-inflammatory and rare diseases, with a lead program in topical treatment for malignant fungating wounds and additional programs in ophthalmology and dermatology.

• Commercializes reformulated topical anti-fungal products in India through licensing and marketing agreements, with manufacturing outsourced to third parties.

• Recently entered into a merger agreement with Vyome Therapeutics, Inc., and an asset sale agreement to divest substantially all assets to Ninjour Health International Limited.

Financial performance and metrics

• ReShape Lifesciences reported $8.7M in revenue for 2023, primarily from the Lap-Band product line, with a net loss of $11.4M and negative cash flows from operations.

• Vyome Therapeutics reported $416K in revenue for 2023, with a net loss of $720K and negative cash flows from operations.

• Both companies have accumulated deficits and have disclosed substantial doubt about their ability to continue as going concerns.

Use of proceeds and capital allocation

• Net proceeds from the IPO will be used for general corporate purposes, including expenses related to the proposed merger and asset sale.

• 50% of net proceeds from any capital stock issuance must be used to prepay amounts owed under a secured convertible note with Ascent Partners Fund LLC.

• Remaining proceeds are at management's discretion, with broad authority over allocation.